Wealth Enhancement Advisory Services’s Takeda Pharmaceutical TAK Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$795K	Buy	48,021 +7,511	+19%	+$124K	﹤0.01%	2260
2026 Q1	$759K	Sell	40,510 -23,467	-37%	-$412K	﹤0.01%	1994
2025 Q4	$1.01M	Sell	63,977 -3,167	-5%	-$45.3K	﹤0.01%	1953
2025 Q3	$971K	Sell	67,144 -505	-0.7%	-$7.5K	﹤0.01%	1889
2025 Q2	$1.04M	Buy	67,649 +1,174	+2%	+$17.3K	﹤0.01%	1730
2025 Q1	$988K	Sell	66,475 -14,772	-18%	-$207K	﹤0.01%	1601
2024 Q4	$1.08M	Sell	81,247 -30,452	-27%	-$418K	﹤0.01%	1497
2024 Q3	$1.59M	Sell	111,699 -12,852	-10%	-$182K	﹤0.01%	1168
2024 Q2	$1.61M	Sell	124,551 -6,353	-5%	-$84.1K	﹤0.01%	1078
2024 Q1	$1.82M	Buy	130,904 +857	+0.7%	+$12.5K	﹤0.01%	981
2023 Q4	$1.86M	Sell	130,047 -5,559	-4%	-$78.9K	0.01%	925
2023 Q3	$2.1M	Buy	+135,606	New	+$2.1M	0.01%	840

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Wealth Enhancement Advisory Services's TAK Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Takeda Pharmaceutical (TAK) stake by 19% in Q2 2026, buying an estimated $124K and bringing the position to 48,021 shares worth $795K. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Wealth Enhancement Advisory Services first reported a position in TAK in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.1M in Q3 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Wealth Enhancement Advisory Services held 48,021 shares of Takeda Pharmaceutical worth $795K as of Q2 2026.
Wealth Enhancement Advisory Services bought 7,511 Takeda Pharmaceutical shares in Q2 2026, an estimated $124K.
Takeda Pharmaceutical made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2260 holding.
Wealth Enhancement Advisory Services first reported a position in Takeda Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
Wealth Enhancement Advisory Services's Takeda Pharmaceutical position peaked at $2.1M in Q3 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.